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1 Introduction
This technical report includes the mathematical model that was constructed
to assess the impact of HPV vaccination strategies. It provides a detailed de-
scription of various model components as they relate to HPV infection, disease
progression, vaccine characteristics, vaccination strategies, and the impact of
HPV vaccination on epidemiologic and economic outcomes. The model allows
for aggregating costs of vaccination, screening, and treatment of the popula-
tion over time, compares them with total health outcomes as measured, for
example, by quality adjusted life years (QALYs), and calculates incremental
cost-e¤ectiveness ratios for various vaccination strategies.
In constructing this model, we reviewed other relevant previous models and
incorporated some of their structures and inputs. These included cervical can-
cer screening cohort models [17, 18, 21, 58, 61, 50], HPV vaccination cohort
models [76, 71, 53, 31, 32], and HPV vaccination dynamic models [39, 28, 5, 19].
This model di¤ers from its predecessors in several ways. First, the approach
is more comprehensive in the sense that it incorporates the epidemiology of
HPV infection, disease, and economics into a single dynamic model. Besides
capturing the direct and indirect herd immunitybenets and costs of vaccina-
tion for the population over time, the added advantage of this latter approach
is its transparency, making critical review of the model and reproducibility of
results [81] feasible without needing to review the actual source code used to
generate the results. In particular, publication of the model includes the math-
ematical equations that summarize in their entirety the actual workings of the
model. These equations can then be entered into any standard mathematical
software package such as Mathematica R (Wolfram Research, Champaign, IL)
or MatLab R (MathWorks, Natick, MA) to reproduce the results. Second, we
also convened an expert panel that reviewed model assumptions and provided
guidance on some aspects of the natural history of disease where there was little
or no clinical evidence. Finally, key inputs in this model are based on data from
recent studies that were not available when previous models were constructed.
For ease of exposition, the model is divided into two major components. The
rst part, which is presented in section 2, is a description of the demographic
aspects of the model. This component of the model is intended to mimic the
current age structure of the US population. Section 3 includes the second part
which consists of the epidemiologic model that describes HPV transmission, and
progression to cervical intraepithelial neoplasia (CIN), cervical cancer, and gen-
ital warts. Because females who undergo hysterectomies for benign conditions
are no longer at risk of developing CIN and cervical cancer but can contribute
to the transmission of HPV, another submodule for benign hysterectomy is cre-
ated. Descriptions of the forces of infection, mixing preferences, and estimates
of the epidemiologic model completes section 3. In sections 4 and 5, we de-
scribe how the epidemiologic and economic impact of screening and vaccination
strategies are assessed.
5
This material, provided by the authors as a supplement to Model for Assessing Human Papillomavirus Vaccination Strategies, 
is not part of Emerging Infectious Diseases contents.
2 The demographic model
2.1 Demographic model structure
The demographic model is a modied version of the initial-boundary-value prob-
lem for age-dependent population growth described in more details in [36]. The
population is divided into n age groups dened by the age intervals [ai 1; ai],
where a1<a2< : : :<an =1 (all the symbols used to describe variables and pa-
rameters are dened in Table1 and 2). The number of individuals Ni(t) at time
t in the age interval [ai 1; ai] is the integral of the age distribution function from
ai 1 to ai. Assuming that the population distribution has reached a steady state
with exponential growth or decay of the form eqt, Hethcote [36] derived a system
of n ordinary di¤erential equations (ODEs) for the sizes of the n age groups.
The simple demographic model used here divides the population into 2 gender
(k = f;m) groups, and 17 age (i = 1; 2; : : : 17) groups (1214, 1517, 1819,
2024, 2529, 3034, 3539,4044, 4549, 5054, 5559, 6064, 6569, 7074,
7579, 8084, and over 85). This age grouping is chosen to accurately account
for patterns of HPV transmission among sexually active groups, cervical cancer
screening patterns, and risk of cervical cancer development among females, and
genital wart occurrence among both males and females. Similar age groupings
have been used by other sexually transmitted diseases models [24, 25]. However,
these models assumed an age of sexual debut of 15 years. By setting the age
of sexual debut to 12 years, our model captures HPV transmission and disease
that occurs before age 15. Recent data suggest age of rst sexual intercourse is
younger than 15 for some teenagers and adolescents. For example, according to
data from the National Survey of Family Growth, 19% of female teenagers had
had sex before age 15 in 1995, compared with 21% of male teenagers [1].
The sexually active population is further stratied into L sexual activity
groups (l = 1; : : : ; L), dened according to the gender-, sexual activity-, and
age-specic rate of sex partner change per unit time ckli. The number of sexual
activity groups considered here is 3 (L = 3). New additions to the sexually active
population enter gender k, sexual activity l, and cervical screening category b
(b = 1; 2) at rate of Bklb. Because males do not participate in cervical screening,
throughout the model the subscript b does not apply to them. For example,
Bmlb = Bml. Individuals die of non-cervical cancer related causes at an age-
and gender-specic per capita death rate ki per year and females with cervical
cancer (categories CCs and DCCs) also have an additional age- and stage-
dependent mortality rate si (s = L;R;D). It is assumed that being in any
CIN or genital warts state does not pose an additional risk of death. Individuals
are transferred between successive age groups at an age- and gender-specic per
capita rate dki per year given by [36]
dki =
ki + q
exp[bandi  (ki + q)]  1
;
where bandi is the number of years within age group i. The annual growth rate
q of this demographic model should also satisfy a modied age-group form of
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the Lotka characteristic equations [36]
Bml = (dm1 + m1 + q)Nml1(0);
Bflb = %b(df1 + f1 + q)Nfl1(0);
where %b denotes the fraction of females entering cervical screening category b,
with %1 + %2 = 1.
After taking into account cervical cancer-induced mortality and replacing
fertility rates in Hethcotes model [36] by recruitment rates into the sexually
active population Bklb, the demographic model is given by the following system
of 102 (= 17 2 3) ODEs:
dNml1=dt = Bml   (m1 + dm1)Nml1
dNmli=dt = dmi 1Nmli 1   (mi + dmi)Nmli
dNfl1=dt =
2X
b=1
Bflb  
X
s
s1(DCCsl1 +
2X
h=1
2X
b=1
CChsl1b)  (f1 + df1)Nfl1
dNfli=dt = dfi 1Nfli 1  
X
s
si(DCCsli +
2X
h=1
2X
b=1
CChslib)  (fi + dfi)Nfli;
i  2, s = L;R;D, where dk17 = 0. All variables, parameters, and subscripts
are dened in Tables 1 and 2 and the text.
2.2 Estimates of the demographic model parameters
Death rates for males and females without cervical cancer are obtained from
Vital Statistics data on gender- and age-specic mortality rates, all races, 2002
[51]. Cancer mortality data are obtained from Surveillance, Epidemiology, and
End Results (SEER) Cancer Statistics age-specic mortality rates, 19972002
[75]. Because the U.S. population grew at a decennial rate of 13.2% between
1990 and 2000, the annual population growth rate was 1.23%. With recruitment
rates into the sexually active population of 1.9% of the male active population
and 1.7% of the female population, the largest annual growth rate q that satises
the solution of the Lotka characteristic equation was 0.5%. Therefore, the annual
growth rate q of this demographic model was set to zero, and Bklb was chosen
to satisfy the Lotka characteristic equation. This will also ensure that variation
in the results across strategies is mainly due to epidemiologic and program
features rather than peculiar characteristics of the demographic model [36].
The sensitivity of the results to this assumption will be tested using an annual
population growth rate of 1.23%.
The initial population size  is set to 100,000, divided equally between males
and females. With the proportion of adults in sexually activity class l given by
!l, the total number of individuals in sexual activity group l is given byX
i
Nkli =
1
2
!l
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Symbol Description
subscripts
k gender (f = females, m = males)
i; j age groups
l;m sexual activity groups
h group of HPV types (16/18 = 1, 6/11 = 2, joint = 12)
s stage of cervical intraepithelial neoplasia (CIN) or cancer
b cervical screening category (never =1, routine = 2)
variables
hkli force of infection with group type h
Xklib susceptible to all types
Y hklib infected with type h, susceptible to the other type
Zhklib immune against type h, susceptible to the other type
Uhklib infected with type h, immune to the other type
Vklib vaccinated against all types
Sklib vaccinated with immunity waned
Whklib vaccinated and infected with type h
Qhklib vaccinated and immune to type h
Phklib vaccinated infected with type h, immune to the other type
Hohli hysterectomy, vaccine, infection status o (e.g., o = X)
CINhslib undetected CIN, grade s, type h
CIShslib undetected carcinoma in situ (CIS), stage s, type h
DCINhslib detected CIN, grade s
DCIShslib detected CIS, stage s
ICINhslib treated CIN, grade s, infected type h
ICIShslib treated CIS, stage s, infected type h
TCINsli treated CIN, grade s, immune
TCISsli treated CIS, stage s, immune
CChslib undetected cervical cancer, stage s
DCCsli detected cervical cancer, stage s
SCCli cervical cancer survivor
GWhslib undetected genital warts
DGWhslib detected genital warts
Nkli number of individuals
Table 1: Description of variables and subscripts
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Symbol Description
demographic parameters
Bklb new entrants into the sexually active population
ki death rate
q rate of population growth
dki transfer rate between age groups
bandi number of years within age group i
behavioral parameters
ckli average rate of sexual partner change
klmij probability of sexual mixing
"1; "2 mixing parameters between age and activity groups
!l proportion of adults in sexual activity class l
%b fraction of females recruits entering cervical screening category b
biological parameters
1=zki average duration of immunity following natural infection
hki recovery from infection with HPV type h
~hki probability of recovering from type h only, given coinfection
hki probability of recovering from type h, given CIN regression
hgki probability of recovering from type h, given genital warts regression
hks progression from HPV infection to CIN states
hcks progression from coinfection to CIN states
hwks progression from breakthrough HPV infection to CIN states
hwcks progression from breakthrough coinfection to CIN states
hgk progression from HPV infection to genital warts
hgwk progression from breakthrough HPV infection to genital warts
hgs probability genital warts are asymptomatic and not treated
his progression between CIN states or cancer
hks regression from CIN states to normal or HPV
hksg regression from CIN state s to CIN state g
hgk regression from genital warts state to normal
hk transmission probability (from sex k
0 to sex k)
rhk relative risk of transmission from vaccinated people
'hk relative risk of infection of a vaccinated person
hk vaccinated person relative rate of infection clearance
1=ki average duration of vaccine protection
si cervical cancer associated death
k0b percentage of 12-year olds vaccinated
kib percentage vaccinated in age group i
ki rate of hysterectomy at age i
sib detection rate of CIN, stage s
hrs recurrence of CIN stage s
 s cure rate of CIN
 s percentage of CIN stage s infected after treatment
s detection of cervical cancer, stage s

s cure rate of cervical cancer, stage s
Table 2: Description of parameters
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Figure 1: Age distribution for 2000 US population 12 years & above and model
(0% annual growth).
By using dki 1Nkli 1   (ki + dki)Nkli with the above equation, we obtain the
initial number of individuals in the youngest age group (1214 years) of each
gender and sexual activity category as
Nkl1(0) =
1
2
!l
0@1 + 17X
i=2
iY
j=2
dkj 1
(dkj + kj)
1A 1 :
The initial numbers of other age groups are given by
Nkli(0) =
dki 1Nkli 1(0)
dki + ki
;
l = 1; 2; 3; i = 2; 3; : : : ; 17.
Note that the size of the male population in the model is always at a steady-
state given by =2 = 50; 000. However, the size of the female population is not
constant during the transient dynamics following vaccination because females
are subject to additional cervical cancer-induced mortality.
The structure of the over 12-year old US population with 0% and 1.23%
annual growth rates, together with data from the 2000 population census are
plotted in Figures 1 and 2, respectively. The model ts well for early age groups,
underestimates around age 40, and overestimates the number of people over age
40 years. It should be noted that the current model does not capture special
characteristics of the US population such as the Baby Boomand migration.
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Figure 2: Age distribution for 2000 US population 12 years & above and model
(1.23% annual growth).
3 The epidemiologic model
The epidemiologic model can be thought of as comprising three components:
HPV transmission, cervical cancer development, and genital warts occurrence.
3.1 HPV transmission
To simplify the analysis, only three ( types 16/18 = 1, types 6/11 = 2, and
coinfection =12) HPV type groupings are modeled. The sexually active host
population of size  at time t is divided into distinct epidemiologic classes, de-
pending on the hosts susceptibility to infection or the hosts status with respect
to infection, disease, screening, and treatment. The HPV component consists
of 17 epidemiologic classes (X;V; Y;W;U; P; Z;Q), with each class further strat-
ied by gender (2 groups), age (17 groups), and sexual activity (3 groups). The
female population has two additional stratications distinguishing females that
are regularly screened from those who are never screened, and females who had
hysterectomies from those with intact cervices. A schematical representation of
the HPV transmission model is shown in Figures 3 and 4.
3.1.1 Susceptible individuals X
New additions to the sexually active population, at a rate of Bklb, enter into
the uninfected (susceptible) category of gender k, sexual activity group l, and
screening category b. A fraction of them is vaccinated at rate kl0b and move
to category V and the remaining fraction enter category X of susceptible indi-
viduals. The model also assumes that a proportion of individuals in other age
11
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Figure 3: A simplied schematic presentation of the unvaccinated compartments
of the HPV model. Individuals enter the population at rate Bklb and a fraction
1   kl0b of them move into the unvaccinated susceptible (X) compartment.
Individuals leave all compartments at rate ki. A susceptible host may be
infected by either or both HPV types. Susceptible individuals acquire type h
infection at rate hkli. A host infected with type h can also be infected with
the other type and move into compartment (Y 12). An infected individual clears
infection with type h at rate hki. Co-infected individuals clear infection with
type h at rate ~hki
12
ki .
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groups and epidemiologic classes is vaccinated at rate klib and move into the
vaccination classes V , W , P , or Q. It is assumed that the vaccine does not con-
fer any therapeutic benets to individuals already infected. Individuals in class
X acquire HPV infection with type h at a gender, sexual activity group, age,
and time dependent rate hkli; where h = 1; 2; 12. In this notation, 
1
kli denotes
infection with types in group 1 (HPV 16/18) and 12kli infection with types in
both groups (HPV 16/18 and HPV 6/11). The number of people in category
Xklib is reduced by infection 
h
kli, vaccination klib, benign hysterectomy ki,
death from other causes ki, and aging dki. The ODEs for category X are
dXkl1b=dt = Bklb(1  kl0b) +
X
h2f1;2;12g
hzk1Z
h
kl1b
 
X
h2f1;2;12g
(hkl1 + kl1b +k1 + k1 + dk1)Xkl1b;
dXklib=dt = dki 1Xkli 1b +
X
h
hzkiZ
h
klib
 
X
h2f1;2;12g
(hkli + klib +ki + ki + dki)Xklib;
i = 2; : : : ; 17; l = 1; 2; 3; k = f;m; b = 1; 2.
3.1.2 Infected individuals Y
When transmission occurs, the unvaccinated X and vaccinated S susceptible
individuals enter the Y class of infected individuals. Individuals enter class
Y after they recover from genital warts at rate gk but are still infected with
probability 1   hgki Females enter class Y if their CIN spontaneously regress
at rate fs but are still infected with probability 1   hki. Individuals leave
this class and enter the Z class of recovered people with immunity when the
infectious period for HPV ends. Unvaccinated infected individuals in the Y
class resolve infection at an age-, gender-, and type-specic per capita rate of
hki. Individuals develop CIN and genital warts at rate 
h
ks and 
h
gk, respectively.
The ODEs for category Y h are
dY hkl1b=dt = 
h
kl1(Xkl1b + Skl1b) + (1  hgk1)hgk(GWhkl1b +DGWhkl1b)
+(1  hk1)
X
s
hks(CIN
h
sl1b +DCIN
h
sl1b)
 (3 hkl1 + kl1b + hk1 +
X
s
hks + 
h
gk +k1 + k1 + dk1)Y
h
kl1b;
dY hklib=dt = dki 1Y
h
kli 1b + 
h
kli(Xklib + Sklib) + (1  hgki)hgk(GWhklib +DGWhklib)
+(1  hki)
X
s
hks(CIN
h
slib +DCIN
h
slib)
 (3 hkli + klib + hki +
X
s
hks + 
h
gk +ki + ki + dki)Y
h
klib:
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The ODEs for coinfection are given by
dY 12kl1b=dt = 
12
kl1(Xkl1b + Skl1b) +
X
h
hkl1Y
3 h
kl1b   (kl1b + 12k1
+
X
s
12cks + 
12
gk +k1 + k1 + dk1)Y
12
kl1b;
dY 12klib=dt = dki 1Y
12
kli 1b +
X
h
hkliY
3 h
klib   (klib + 12ki
+
X
s
12cks + 
12
gk +ki + ki + dki)Y
12
klib:
3.1.3 Partially immune individuals Z
Individuals enter class Z when recovered from CIN or genital warts and having
resolved infection. It is assumed that immunity derived from natural infection
can be temporary, and individuals in the Z category can eventually move to the
susceptible class X at rate hzki. Individuals in the Z class who are susceptible
to one type can be infected with that type and move to class U . The ODEs for
category Zh are
dZhkl1b=dt = 
h
k1Y
h
kl1b +
3X
s=1
fhk1hks(CINhsl1b +DCINhsl1b) + hk1ICINhsl1bg
+
2X
s=1
hk1ICIS
h
sl1b + 
h
gk1
h
gk(GW
h
kl1b +DGW
h
kl1b)
 (3 hkl1 + kl1b +k1 + hzk1 + k1 + dk1)Zhkl1b;
dZhklib=dt = dki 1Z
h
kli 1b + 
h
kiY
h
klib +
3X
s=1
fhkihks(CINhslib +DCINhslib)
+hkiICIN
h
slibg+
2X
s=1
hkiICIS
h
slib + 
h
gki
h
gk(GW
h
klib +DGW
h
klib)
 (3 hkli + klib +ki + hzki + ki + dki)Zhklib:
The ODEs for the fully immune individuals Z12 are
dZ12kl1b=dt = ~
12
k1
12
k1Y
12
kl1b +
X
h
hk1U
h
kl1b
 (kl1b +k1 + 12zk1 + k1 + dk1)Z12kl1b;
dZ12klib=dt = ~
12
ki
12
kiY
12
klib +
X
h
hkiU
h
klib   (klib +ki + 12zki + ki + dki)Z12klib:
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Figure 4: Schematic presentation of the vaccinated compartments of the HPV
model. A fraction of the new susceptible recruits kl0b are vaccinated and
move into compartment V . The vaccine provides incomplete protection against
the high-risk and low-risk types at rates 1   '1ki and 1   '2ki, respectively. A
vaccinated person moves into compartment W upon infection with any type.
Upon clearance of infection at rate hki faster than natural infection, the person
moves to compartment Q. The vaccine-induced immunity wanes at rate ki.
3.1.4 Infected individuals with partial immunity U
The number of people in category U is reduced by vaccination klib, resolution
of infection hki, and onset of disease. The ODEs for category U are
dUhkl1b=dt = 
h
kl1Z
3 h
kl1b + ~
3 h
k1 
12
k1Y
12
kl1b
 (kl1b + hk1 +
X
s
hks + 
h
gk +k1 + k1 + dk1)U
h
kl1b;
dUhklib=dt = dki 1U
h
kli 1b + 
h
kliZ
3 h
klib + ~
3 h
ki 
12
kiY
12
klib
 (klib + hki +
X
s
hks + 
h
gk +ki + ki + dki)U
h
klib:
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3.1.5 Vaccinated individuals V
When 12-year olds are o¤ered the vaccine, a fraction of them kl0 are vacci-
nated and move into the vaccination class V . Also, individuals in class X are
vaccinated at rate kl1b and enter category V . The vaccine-induced immunity
of those in the vaccinated class V wanes, so that people eventually move to the
susceptible class S at an age- and gender-dependent rate ki. It is assumed
that when an individual loses vaccine-derived immunity, the individual becomes
susceptible to infection with any of the types. Vaccinated individuals can also
experience a break-through infection and enter the class W of infective people
at per capita rate 'hk
h
kli. The ODEs for category V are
dVkl1b=dt = Bklbkl0b + kl1bXkl1b   (
X
h
'hk
h
kl1 + k1 +k1 + k1 + dk1)Vkl1b;
dVklib=dt = dki 1Vkli 1b + klibXklib   (
X
h
'hk
h
kli + ki +ki + ki + dki)Vklib:
3.1.6 Vaccinated individuals with waned immunity S
Individuals in this class can get infected at the same rate as those in the sus-
ceptible class X. The ODEs for class S are
dSkl1b=dt = k1Vkl1b   (
X
h
hkl1 +k1 + k1 + dk1)Skl1b;
dSklib=dt = dki 1Skli 1b + kiVklib   (
X
h
hkli +ki + ki + dki)Sklib:
3.1.7 Infectious vaccinated individuals W
Individuals infected with one type and susceptible to the other move category
W when vaccinated. Vaccinated individuals are infected at an age- and gender-
specic rate 'hk times slower, and recover from infection at a rate 
h
ki faster
than unvaccinated infected individuals and move to class Q. They also progress
to disease at a di¤erent rate (hwks or 
h
gkw) compared with that of infected
unvaccinated individuals. The ODEs for category W are
dWhkl1b=dt = '
h
k
h
kl1Vkl1b + kl1bY
h
kl1b   ('3 hk 3 hkl1 + hk1hk1
+
X
s
hwks + 
h
gkw +k1 + k1 + dk1)W
h
kl1b;
dWhklib=dt = dki 1W
h
kli 1b + '
h
k
h
kliVklib + klibY
h
klib   ('3 hk 3 hkli
+hki
h
ki +
X
s
hwks + 
h
gkw +ki + ki + dki)W
h
klib:
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The ODEs for coinfection W 12 are
dW 12kl1b=dt = '
1
k'
2
k
12
kl1Vkl1b +
X
h
'hk
h
kl1W
3 h
kl1b + kl1bY
12
kl1b   (12k112k1
+
X
s
12wcks + 
12
kgw +k1 + k1 + dk1)W
12
kl1b;
dW 12klib=dt = dki 1W
12
kli 1b + '
1
k'
2
k
12
kliVklib +
X
h
'hk
h
kliW
3 h
klib + klibY
12
klib
 (12ki12ki +
X
s
12wcks + 
12
gwk +ki + ki + dki)W
12
klib:
3.1.8 Vaccinated, partially immune individuals Q
Infected vaccinated individuals (category W ) recovering from infection and in-
dividuals with natural immunity to one type (category Z) receiving the vaccine
move to category Q. Individuals in this class who are susceptible to one type
can be infected with that type and move to class P . The ODEs for category Q
are
dQhkl1b=dt = 
h
k1
h
k1W
h
kl1b + kl1bZ
h
kl1b   ('3 hk 3 hkl1 +k1 + k1 + dk1)Qhkl1b;
dQhklib=dt = dki 1Q
h
kli 1b + 
h
ki
h
kiW
h
klib + klibZ
h
klib
 ('3 hk 3 hkli +ki + ki + dki)Qhklib:
The ODEs for Q12 are
dQ12kl1b=dt = 
12
k1~
12
k1
12
k1W
12
kl1b +
X
h
hk1P
h
kl1b + kl1bZ
12
kl1b
 (k1 + k1 + dk1)Q12klib;
dQ12klib=dt = dki 1Q
12
kli 1b + 
12
ki ~
12
ki
12
kiW
12
klib +
X
h
hkiP
h
klib + klibZ
12
klib
 (ki + ki + dki)Q12klib:
3.1.9 Vaccinated, infected individuals with partial immunity P
Coinfected vaccinated individuals recovering from one infection (categoryW 12),
vaccinated individuals (category Q) getiing infected, and individuals infected
with one type (category Z) receiving the vaccine move to category P . The
ODEs for category P are
dPhkl1b=dt = '
h
k
h
kl1Q
3 h
kl1b + 
3 h
k1 ~
3 h
k1 
12
k1W
12
kl1b + kl1bU
h
kl1b
 (hk1hk1 +
X
s
hwks + 
h
gwk +k1 + k1 + dk1)P
h
kl1b;
dPhklib=dt = dki 1P
h
kli 1b + '
h
k
h
kliQ
3 h
klib + 
3 h
ki ~
3 h
ki 
12
kiW
12
klib + klibU
h
klib
 (hkihki +
X
s
hwks + 
h
gwk +ki + ki + dki)P
h
klib:
Note that for males, mi = 
h
wms = 
h
ms = 
h
ms = 
h
cms = 0.
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3.2 Cervical intraepithelial neoplasia
Infected females (whether vaccinated or not) can develop CIN and move to the
CIN segment of the model. There are several states that represent the true
histological health status of a female: infected with a normal cervix, CIN grade
1 (CIN 1), CIN grade 2 (CIN 2), and CIN grade 3 (CIN 3). Females in the
CIN and cancer stages are further classied into unknown, detected, or treated
classes. There are also two additional absorbing states where only females who
are no longer at risk of developing cervical cancer enter. These are benign
hysterectomy for reasons other than cervical cancer (at an age-specic rate f i)
and treated and cured CIN at stage-specic rate (1    s) s. Females in these
two states are considered to be at no risk of developing cervical cancer [61].
However, females with hysterectomies for benign conditions can be infected and
are at risk of developing genital warts [9]. Further, to take into account the fact
that treatment of CIN does not completely eliminate the virus, another category
of women with treated CIN who remain infected after treatment (ICIN) was
created. Females enter this category from the detected state at rate  s s and
stay there until their CIN recurs at rate hr s or they clear infection.
An infected female with a normal cervix can only directly progress to CINhs
(at rate hfs if unvaccinated or 
h
wfs if vaccinated), die due to causes other than
cervical cancer, or remain infected without progressing to CIN (Figure 5). The
respective progression rates given coinfection are hcfs and 
h
cwfs. For the base
case, it is assumed that cases with coinfection progress to CIN according to the
rate of high-risk HPV types. That is, 1cfs = 
1
fs, 
2
cfs = 0, 
1
cwfs = 
1
wfs, and
2cwfs = 0. It is assumed that infected females classied as CIN can progress only
to higher CIN states (CIN1 to CIN2, CIN2 to CIN3), or cancer (CIN3 to cervical
carcinoma in situ, CIS) at rate hsi, regress to normal at rate 
h
s or CIN state g
at rate hsg, die from other causes, be detected at rate sib and be treated and
cured at rate  s, or remain in that CIN state. Coinfection of females in CIN and
cervical cancer states is not modeled. It is assumed that regression from CIN
states does not necessarily imply recovery from HPV infection. A female whose
CIN regresses to normal but is still infected moves to the infected category Y hfi
at an age- and stage-specic rate hs (1 hfi) regardless of her vaccination status.
Only mutual regression from both HPV and CIN confers immunity against that
type. Females regressing from CIN, whose HPV infection clears, move into class
Z at an age- and state-specic rate hfi
h
s (s = 1; 2; 3).
The cervical neoplasia segment includes several epidemiologic classes (CINs,
DCINs, TCINs, ICINs; s = 1; 2; 3), with each class further subdivided into
age (= 17), sexual activity (= 3), and screening (= 2) groups.
3.2.1 Undetected CIN CINs
The number of females with undetected CIN increases as infected females de-
velop disease or fail treatment. Screening sib, spontaneous regression hfs, and
progression to higher disease grades hsi reduce the number of females in this
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Figure 5: A simplied schematic presentation of the cervical intraepithelial
neoplasia (CIN) model. Females can develop cervical intraepithelial neoplasia
(CIN) and progress though several histological states: infected with a normal
cervix, CIN 1, CIN 2, CIN 3, and cervical carcinoma in situ (CIS). Females with
CIN can regress to normal with or without infection.
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category. Equations for undetected CIN are
dCINh1l1b=dt = 
h
f1(Y
h
fl1b + U
h
fl1b) + 
h
cf1Y
12
fl1b + 
h
wf1(W
h
fl1b + P
h
fl1b)
+hwcf1W
12
fl1b + 
h
r1ICIN
h
1l1b + 
h
f21CIN
h
2l1b + 
h
f31CIN
h
3l1b
 (hf1 + h11 +f1 + 11b + f1 + df1)CINh1l1b;
dCINh1lib=dt = dfi 1CIN
h
1li 1b + 
h
f1(Y
h
flib + U
h
flib) + 
h
cf1Y
12
flib
+hwfi(W
h
flib + P
h
flib) + 
h
wcfiW
12
flib + rsICIN
h
1lib
+hf21CIN
h
2lib + 
h
f31CIN
h
3lib
 (hf1 + h1i +fi + 1ib + fi + dfi)CINh1lib;
dCINhsl1b=dt = 
h
fs(Y
h
fl1b + U
h
fl1b) + 
h
cfsY
12
fl1 + 
h
wfs(W
h
fl1b + P
h
fl1b)
+hwcfsW
12
fl1b + 
h
rsICIN
h
1l1b
+hs 11(CIN
h
s 1l1b +DCIN
h
s 1l1b)
+hfs+1sCIN
h
s+1l1b   (hfs + hfss 1 + hfss 2 + hs1 +f1
+s1b + f1 + df1)CIN
h
sl1b;
dCINhslib=dt = dfi 1CIN
h
sli 1b + 
h
fs(Y
h
flib + U
h
flib) + 
h
cfsY
12
flib
+hwfs(W
h
flib + P
h
flib) + 
h
wcfiW
12
flib + 
h
rsICIN
h
1lib
+hs 1i(CIN
h
s 1lib +DCIN
h
s 1lib) + 
h
fs+1sCIN
h
s+1lib
 (hfs + hfss 1 + hfss 2 + hsi +fi
+sib + fi + dfi)CIN
h
slib;
where s = 2; 3, and hf43 = 
h
f20 = 0.
3.2.2 Detected CIN DCINs
Detection of CIN occurs only as result of screening at rate sib. This rate
depends on screening coverage and the characteristics of the screening and di-
agnostic tests. If it does not regress at rate hfs or is treated at rate  s, CIN
can progress to a higher grade at rate hsi. Equations for detected CIN are
dDCINhsl1b=dt = s1bCIN
h
sl1b   (hfs + hs1 +f1 +  s + f1 + df1)DCINhsl1b;
dDCINhslib=dt = dfi 1DCIN
h
sli 1b + sibCIN
h
slib
 (hfs + hsi +fi +  s + fi + dfi)DCINhslib;
where s = 1; 2; 3.
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3.2.3 Treated CIN TCINs
It is assumed that treatment does not completely eliminate infection. A fraction
of treated females  s will remain infectious after treatment and move to the
category treated but infectious ICINs. Equations for treated CIN are
dTCINsl1=dt = (1   s) s
X
h
X
b
DCINhsl1b   (f1 + f1 + df1)TCINsl1;
dTCINsli=dt = dfi 1TCINli 1 + (1   s) s
X
h
X
b
DCINhslib
 (fi + fi + dfi)TCINsli;
where s = 1; 2; 3.
3.2.4 Treated CIN but infectious ICINs
CIN for females in this category can recur at rate rs and move to category
CINs. Infection can also resolve and individuals enter category Zh. Equations
for treated but infectious CIN are
dICINhsl1b=dt =  s sDCIN
h
sl1b   (hf1 + hrs +1 + f1 + df1)ICINhsl1b;
dICINhslib=dt = dfi 1ICIN
h
sli 1b +  s sDCIN
h
slib
 (hfi + hrs +i + fi + dfi)ICINhslib;
where s = 1; 2; 3.
3.3 Cervical carcinoma in situ
It is assumed that females classied as CIN can progress to carcinoma in situ
(CIS). Because females spend, on average, a long time in CIS, two CIS states
are modeled (CIS 1 and CIS 2). It is assumed that regression from CIS states
is not possible. CIS is further divided into several epidemiologic classes (CISs,
DCISs, TCISs, ICISs; s = 1; 2), with each class further subdivided into age
(= 17), sexual activity (= 3), and screening (= 2) groups.
3.3.1 Undetected CIS CISs
The number of females with undetected CIS increases as they progress from
CIN 3 (severe dysplasia) or fail treatment. Screening 3+sib and progression
to higher disease grades h3+si reduce the number of females in this category,
s = 1; 2. Equations for undetected CIS are
dCISh1l1b=dt = 
h
r4ICIS
h
1l1b + 
h
31(CIN
h
3l1b +DCIN
h
3l1b)
 (h41 +f1 + 41b + f1 + df1)CISh1l1b;
dCISh1lib=dt = dfi 1CIS
h
1li 1b + 
h
r4ICIS
h
1lib + 
h
3i(CIN
h
3lib +DCIN
h
3lib)
 (h4i +fi + 4ib + fi + dfi)CINh1lib;
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dCISh2l1b=dt = 
h
r5ICIS
h
2l1b + 
h
41(CIS
h
1l1b +DCIS
h
1l1b)
 (h51 +f1 + 51b + f1 + df1)CISh2l1b;
dCISh2lib=dt = dfi 1CIS
h
2li 1b + 
h
r5ICIS
h
2lib + 
h
4i(CIS
h
2lib +DCIS
h
2lib)
 (h51 +f1 + 51b + f1 + df1)CISh2l1b:
3.3.2 Detected CIS DCISs
Detection of CIS occurs only as result of screening at rate 3+sib. If it is not
treated and cured at rate  3+s, CIS can progress to a higher grade h3+si or
cancer. Equations for detected CIS are
dDCIShsl1b=dt = 3+s1bCIS
h
sl1b   (h3+s1 +f1 +  3+s + f1 + df1)DCIShsl1b;
dDCIShslib=dt = dfi 1DCIS
h
sli 1b + 3+sibCIS
h
slib
 (h3+si +fi +  3+s + fi + dfi)DCIShslib;
where s = 1; 2.
3.3.3 Treated CIS TCISs
It is assumed that treatment does not completely eliminate infection. A fraction
of treated females  3+s will remain infectious after treatment and move to the
category treated but infectious ICISs. Equations for treated CIS are
dTCISsl1=dt = (1   3+s) 3+s
X
h
X
b
DCIShsl1b   (f1 + f1 + df1)TCISsl1;
dTCISsli=dt = dfi 1TCISli 1 + (1   3+s) 3+s
X
h
X
b
DCIShslib
 (fi + fi + dfi)TCISsli;
where s = 1; 2.
3.3.4 Treated CIS but infectious ICISs
It is assumed that CIS recurs at rate hr3+s and women with recuring CIS move
to category CISs. Infection can also resolve and individuals enter category Zh.
Equations for treated but infectious CIS are
dICIShsl1b=dt =  3+s 3+sDCIS
h
sl1b   (hf1 + hr3+s +1 + f1 + df1)ICIShsl1b;
dICIShslib=dt = dfi 1ICIS
h
sli 1b +  3+s 3+sDCIN
h
slib
 (hfi + hr3+s +i + fi + dfi)ICIShslib;
where s = 1; 2.
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Figure 6: Schematic presentation of the cervical cancer (CC) model. Females
can develop cervical cancer from carcinoma in situ stage 2 (CIS2) and progress
though several cancer stages: early invasive local cervical cancer, regional late
invasive cervical cancer, and distant late invasive cervical cancer. If detected,
cancer cases are treated. After successful treatment, those cases move to the
cancer survivors compartment. Cancer cases die at rate si.
3.4 Cervical cancer
There are several states that represent the health status of a female with cervical
cancer: localized cervical cancer (LCC), regional cervical cancer (RCC), distant
cervical cancer (DCC), and cancer survivors who are free from cancer (Figure
6). Females in cancer stages are further classied into unknown, detected, or
treated classes. A female with an invasive cancer can progress only to the next
higher cancer state CChs (LCC to RCC, RCC to DCC) at rate si (s = L;R),
her cervical cancer is detected at rate sib and successfully treated and move
to the cancer survivors state at rate 
s, die from cancer at rate si, or stay in
that undetected cancer state. Regression from invasive cancer to normal is not
allowed. It is assumed that females who were successfully treated for invasive
cancer are no longer infectious.
3.4.1 Undetected cervical cancer CCs
CIS 2 cases that are not detected and treated can progress to localized cervical
cancer at rate h5i. Undetected cancer cases, if undetected at rate sib, can
progress to more advanced stages at rate s, s = L;R. Cervical cancer has an
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additional mortality rate si. Equations for undetected CC are
dCChLl1b=dt = 
h
51(CIS
h
2l1b +DCIS
h
2l1b)  (L + L1b + L1 + f1 + df1)CChLl1b;
dCChLlib=dt = dfi 1CC
h
Lli 1b + 
h
5i(CIS
h
5lib +DCIS
h
5lib)
 (L + Lib + Li + fi + dfi)CChLlib;
dCChRl1b=dt = LCC
h
Ll1b   (R + R1b + R1 + f1 + df1)CChRl1b;
dCChRlib=dt = dfi 1CC
h
Rli 1b + LCC
h
Llib   (D + Rib + Ri + fi + dfi)CChRlib;
dCChDl1b=dt = RCC
h
Rl1b   (D1b + D1 + f1 + df1)CChDl1b;
dCChDlib=dt = RCC
h
Rlib + dfi 1CC
h
Dli 1b   (Dib + Di + fi + dfi)CChDlib;
where i  2.
3.4.2 Detected cervical cancer DCCs
Detected cancer cases are treated and cured at rate 
s and move to the cancer
survivors category SCC. Equations for detected CC are
dDCCsl1=dt =
X
h
X
b
s1bCC
h
sl1b   (
s + s1 + f1 + df1)DCCsl1;
dDCCsli=dt = dfi 1DCCsli 1 +
X
h
X
b
sibCC
h
slib   (
s + si + fi + dfi)DCCsli;
where s = L;R;D.
3.4.3 Cervical cancer survivors SCC
Equations for cancer survivors are
dSCCl1=dt =
X
s

sDCCsl1   (f1 + df1)SCCl1;
dSCCli=dt = dfi 1SCCli 1 +
X
s

sDCCsli   (fi + dfi)SCCli:
3.5 Genital warts GW
Individuals (whether vaccinated or not) infected with HPV 6/11 can develop
genital warts at rate 2gwk and move to the genital warts class GW . Of those,
a proportion gs will remain asymptomatic and will not be treated whereas the
rest will be recognized and treated. Individuals recovering from genital warts at
rate 2kg move to class Z. It is assumed that only infection with HPV 6/11 can
cause genital warts whereas infection with HPV 16/18 does not lead to genital
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warts [84]. The asymptomatic genital warts class consists of the following ODEs
dGW 2kl1b=dt = gs(
2
gk(Y
2
kl1b + U
2
kl1b) + 
12
gkY
12
kl1b + 
2
gwk(W
2
kl1b + P
2
kl1b)
+12gwkW
12
kl1b)  (2gk +k1 + k1 + dk1)GW 2kl1b;
dGW 2klib=dt = dki 1GW
2
kli 1b + gs(
2
gk(Y
2
klib + U
2
klib) + 
12
gkY
12
klib
+2gwk(W
2
klib + P
2
klib) + 
12
gwkW
12
klib)
 (2gk +ki + ki + dki)GW 2klib:
The symptomatic genital warts class consists of the following ODEs
dDGW 2kl1b=dt = (1  gs)(2gk(Y 2kl1b + U2kl1b) + 12gkY 12kl1b
+2gwk(W
2
kl1b + P
2
kl1b) + 
12
gwkW
12
kl1b)
 (2gk +k1 + k1 + dk1)DGW 2kl1b;
dDGW 2klib=dt = dki 1GW
2
kli 1b + (1  gs)(2gk(Y 2klib + U2klib)
+12gkY
12
klib + 
2
gwk(W
2
klib + P
2
klib) + 
12
gwkW
12
klib)
 (2gk +ki + ki + dki)DGW 2klib:
3.6 Hysterectomies for benign conditions
Females who undergo hysterectomies for benign conditions move to the H com-
partment and stay there at no risk of developing CIN or cervical cancer. How-
ever, females in this compartment can be infected, can transmit infection, and
can develop genital warts. There are several epidemiologic classes within the
H compartment (HX;HV;HS;HY;HW;HU;HP;HZ;HQ;HGW ), with each
class further stratied by age (=17) and sexual activity (=3) groups.
3.6.1 Susceptible individuals HX
The ODEs for category HX are
dHXfl1=dt = f1
X
b
Xfl1b +
X
h
hzf1HZ
h
fl1b   (
X
h
hfl1 + f1 + df1)HXfl1;
dHXfli=dt = dfi 1HXfli 1 +fi
X
b
Xflib +
X
h
hzfiHZ
h
flib
 (
X
h
hfli + fi + dfi)HXfli;
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3.6.2 Infected individuals HY
The ODEs for category HY are
dHY hfl1=dt = 
h
fl1(HXfl1 +HSfl1)  (3 hfl1 + hf1 + hgf + f1 + df1)HY hfl1
+f1(
X
b
Y hfl1b +
X
s
(CINhsl1b +DCIN
h
sl1b + ICIN
h
sl1b));
dHY hfli=dt = dfi 1HY
h
fli 1 + 
h
fli(HXfli +HSfli)
 (3 hfli + hfi + hgf + fi + dfi)HY hfli
+fi(
X
b
Y hflib +
X
s
(CINhslib +DCIN
h
slib + ICIN
h
slib)):
The ODEs for HY 12 are
dHY 12fl1=dt = 
12
fl1(HXfl1 +HSfl1) +
X
h
hfl1HY
3 h
fl1 +f1
X
b
Y 12fl1b
 (12f1 + 12gf + f1 + df1)HY 12fl1;
dHY 12fli=dt = dfi 1HY
12
fli 1 + 
12
fli(HXfli +HSfli) +
X
h
hfliHY
3 h
fli
+fi
X
b
Y 12flib   (12fi + 12gf + fi + dfi)HY 12fli:
3.6.3 Partially immune individuals HZ
The ODEs for category HZ are
dHZhfl1=dt = 
h
f1HY
h
fl1 +f1
X
b
Zhfl1b + 
h
gf (HGW
h
fl1 +DHGW
h
fl1)
 (3 hfl1 + hzf1 + f1 + df1)HZhfl1;
dHZhfli=dt = dfi 1HZ
h
fli 1 + 
h
fiHY
h
fli +fi
X
b
Zhflib
+hgf (HGW
h
fli +DHGW
h
fli)  (3 hfli + hzfi + fi + dfi)HZhfli:
The ODEs for HZ12 are
dHZ12fl1=dt = ~
12
f1
12
f1HY
12
fl1 +
X
h
hf1HU
h
fl1 +f1(
X
b
Z12fl1b +
X
s
TCINsl1)
 (12zf1 + f1 + df1)HZ12fl1;
dHZ12fli=dt = dfi 1HZ
12
fli 1 + ~
12
fi
12
fiHY
12
fli +
X
h
hfiU
h
flib
+fi(
X
b
Z12flib +
X
s
TCINsli)  (hzfi + fi + dfi)HZ12fli:
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3.6.4 Infected individuals with partial immunity HU
The ODEs for category HU are
dHUhfl1=dt = 
h
fl1HZ
3 h
fl1 + ~
3 h
f1 
12
f1HY
12
fl1 +f1
X
b
Uhfl1b
 (hf1 + hgf + f1 + df1)HUhfl1;
dHUhfli=dt = dfi 1HU
h
fli 1 + 
h
fliHZ
3 h
fli + ~
3 h
fi 
12
fiHY
12
fli
+fi
X
b
Uhflib   (hfi + hgf + fi + dfi)HUhfli:
3.6.5 Vaccinated individuals HV
The ODEs for category HV are
dHVfl1=dt = f1
X
b
V hfl1b   (
X
h
'hf
h
fl1 + f1 + f1 + df1)HVfl1;
dHVfli=dt = dfi 1HVfli 1 +fi
X
b
V hflib   (
X
h
'hf
h
fli + fi + fi + dfi)HVfli:
3.6.6 Vaccinated individuals with waned immunity HS
The ODEs for classes HS are
dHSfl1=dt = f1HVfl1 +f1
X
b
Sfl1b   (
X
h
hfl1 +f1 + f1 + df1)HSfl1;
dHSfli=dt = dfi 1HSfli 1 + fiHVfli +fi
X
b
Sflib   (
X
h
hfli + fi + dfi)HSfli:
3.6.7 Infectious vaccinated individuals HW
The ODEs for category HW are
dHWhfl1=dt = '
h
f
h
fl1HVfl1 +f1
X
b
Whfl1b
 ('3 hf 3 hfl1 + hf1hf1 + hgfw + f1 + df1)HWhfl1;
dHWhfli=dt = dfi 1HW
h
fli 1 + '
h
f
h
fliHVfli +fi
X
b
Whflib
 ('3 hf 3 hfli + hfihfi + hgfw + fi + dfi)HWhfli;
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The ODEs for HW 12 are
dHW 12fl1=dt = '
1
f'
2
f
12
fl1HVfl1 +
X
h
'hf
h
fl1HW
3 h
fl1 +f1
X
b
W 12fl1b
 (12f112f1 + 12gwf + f1 + df1)HW 12fl1;
dHW 12fli=dt = dfi 1HW
12
fli 1 + '
1
f'
2
f
12
fliHVfli +
X
h
'hf
h
fliHW
3 h
fli
+fi
X
b
W 12flib   (12fi12fi + 12gwf + fi + dfi)HW 12fli:
3.6.8 Vaccinated, partially immune individuals HQ
The ODEs for category HQ are
dHQhfl1=dt = 
h
f1
h
f1HW
h
fl1 +f1
X
b
Qhfl1b
 ('3 hf 3 hfl1 + f1 + df1)HQhfl1;
dHQhfli=dt = dfi 1HQ
h
fli 1 + 
h
fi
h
fiHW
h
fli +fi
X
b
Qhflib
 ('3 hf 3 hfli + fi + dfi)HQhfli;
The ODEs for HQ12 are
dHQ12fl1=dt = 
12
f1~
12
f1
12
f1HW
12
fl1 +
X
h
hf1HP
h
fl1 +f1
X
b
Q12fl1b
 (f1 + df1)HQ12fli;
dHQ12fli=dt = dfi 1HQ
12
fli 1 + 
12
fi~
12
fi
12
fiHW
12
fli +
X
h
hfiHP
h
fli +fi
X
b
Q12flib
 (fi + dfi)HQ12fli:
3.6.9 Vaccinated, infected individuals with partial immunity HP
The ODEs for category HP are
dHPhfl1=dt = '
h
f
h
fl1HQ
3 h
fl1 + 
3 h
f1 ~
3 h
f1 HW
12
fl1
+f1
X
b
Phfl1b   (hf1hf1 + hgwf + f1 + df1)HPhfl1;
dHPhfli=dt = dfi 1HP
h
fli 1 + '
h
f
h
fliHQ
3 h
fli + 
3 h
fi ~
3 h
fi HW
12
fli
+fi
X
b
Phflib   (hfihfi + hgwf + fi + dfi)HPhflib:
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3.6.10 Genital warts GW
The genital warts class consists of the following di¤erential equations
dHGW 2kl1b=dt = gs(
2
gk(HY
2
kl1b +HU
2
kl1b) + 
12
gkHY
12
kl1b
+2gwk(HW
2
kl1b +HP
2
kl1b) + 
12
gwkHW
12
kl1b) + k1GW
2
klib
 (2gk + k1 + dk1)HGW 2kl1b;
dHGW 2klib=dt = dki 1HGW
2
kli 1b + gs(
2
gk(HY
2
klib +HU
2
klib) + 
12
gkHY
12
klib
+2gwk(HW
2
klib +HP
2
klib) + 
12
gwkHW
12
klib) + kiGW
2
klib
 (2gk + ki + dki)HGW 2kl1b;
dDHGW 2kl1b=dt = (1  gs)(2gk(HY 2kl1b +HU2kl1b) + 12gkHY 12kl1b
+2gwk(HW
2
kl1b +HP
2
kl1b) + 
12
gwkHW
12
kl1b) + k1HGW
2
kl1b
 (2gk + k1 + dk1)DHGW 2kl1b;
dDHGW 2klib=dt = dki 1HGW
2
kli 1b + (1  gs)(2gk(HY 2klib +HU2klib)
+12gkHY
12
klib + 
2
gwk(HW
2
klib +HP
2
klib) + 
12
gwkHW
12
klib)
+kiHGW
2
klib   (2gk + ki + dki)DGW 2klib:
3.7 Forces of HPV infection 
The rate at which susceptible individuals acquire infection with type h (per
capita force of infection) hkli is gender, sexual activity, age, and time dependent.
The rate hkli at which individuals of gender k, sexual activity group l, age class
i, at time t acquire infection with type h depends on the number of gender
partnerships and the way they form partnerships with individuals of the opposite
gender k0, the fraction of infected sex partners, and the transmission probability
hk per partnership. The force of HPV infection 
h
kli is given by
hmli = 
h
m
17X
j=1
3X
a=1
cmlaijmlaij
 
2X
b=1
[rf (W
h
fajb + P
h
fajb +W
12
fajb) + Y
h
fajb
+Y 12fajb + U
h
fajb +
X3
s
 
CINhsajb +DCIN
h
sajb + ICIN
h
sajb

+GWhfajb
+DGWhfajb +
L;R;DX
s
CChsajb] +
X2
s
 
CIShsajb +DCIS
h
sajb + ICIS
h
sajb

]
+rf (HP
h
faj +HW
h
faj +HW
12
faj) +HU
h
faj +HY
12
faj
+ HGWhfaj +DHGW
h
faj

=Nfaj ;
hfli = 
h
f
17X
j=1
3X
a=1
cflaijflaij
 
Y hmaj + U
h
maj + Y
12
maj +GW
h
maj +DGW
h
maj
+ rm
 
Whmaj +W
12
maj + P
h
maj

=Nmaj ;
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h = 1; 2. Coinfection occurs at rate
12mli = 
1
m
2
m
17X
j=1
3X
a=1
cmlaijmlaij  
HY 12faj + rfHW
12
faj +
2X
b=1
(Y 12fajb + rfW
12
fajb)
!
=Nfaj ;
12fli = 
1
f
2
f
17X
j=1
3X
a=1
cflaijflaij
 
Y 12maj + rmW
12
maj

=Nmaj :
3.8 Mixing preferences
3.8.1 Mixing matrix 
The way sex partnerships are formed is governed by the conditional probabil-
ity matrix . Thus, klmij is the probability of someone of gender k, sexual
activity group l, age class i having a partner from the opposite gender from
sexual activity group m and age class j. This depends on the proportion of
sex partners from the opposite gender from sexual activity group m and age
class j, ck0mjNk0mj(0), in the total sexually active population. In generating
the mixing matrix , the parameters 1 and 2 are used to depict the degree of
assortative mixing between age and sexual activity groups, respectively. Thus,
mixing is fully assortative ( is the identity matrix klmij = lmij , where ij
is the Kronecker delta) if 1 = 2 = 0 and proportionate when 1 = 2 = 1
[24, 25, 26, 27]. The mixing matrix klmij is given by
klmij =
 
(1  1)ij + 1
P3
s=1 ck0sjNk0sj(0)P17
u=1
P3
a=1 ck0auNk0au(0)
!
 
(1  2)lm + 2
P17
u=1 ck0muNk0mu(0)P17
u=1
P3
a=1 ck0auNk0au(0)
!
:
The model should satisfy the constraints balancing the supply of and de-
mand for sexual partnerships: cklmijklmijNkli = ck0mljik0mljiNk0mj . This is
accomplished by specifying the mean rates of sex partner change as functions
of the initial imbalance in the supply and demand of sex partnerships. Thus,
cklmij = ckliB
0:5
lmij ;
where
Blmij =
ck0mjk0mljiNk0mj(0)
ckliklmijNkli(0)
:
The di¤erential e¤ects of cervical cancer-induced mortality are also likely
to cause an imbalance between the demand for and supply of sex partnerships.
There are few options for rectifying this. One option is to let the rates of sex
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partner change and mixing pattern of one gender vary over time so as to satisfy
the above constraints. Another option is to x the mixing patterns of both
sexes and to let their rates of sex partner change vary over time so as to balance
the supply of and demand for sex partnerships [25]. However, this latter option
requires adding additional di¤erential equations that may considerably increase
the size of the model. Because of this additional complexity only the former
option is tried. Thus,
ck0mlji(t) =
cklmijklmijNkli(t)
k0mljiNk0mj(t)
:
In the sensitivity analysis, the gender that will be chosen rst will be varied to
test the robustness of the results.
3.8.2 Estimates of the mixing matrix
Even though the crucial role of the mixing matrix in the spread of many sexually
transmitted infections has been repeatedly emphasized before [24, 25, 26, 27],
there are no adequate data to generate such a matrix. The current analysis
follows previous work in this area by examining the range of patterns that are
likely to arise in practice. This range is governed by the parameters 1 and 2
whose respective values are set to 0.6 and 0.7 in the baseline analysis and varied
over a wide range in the sensitivity analysis. These estimates are obtained from
the National Health and Social Life Survey (NHSLS) [55, 63, 64]. Higher values
for 2 are reported for high-risk populations. For example, Garnett et al [26]
estimated a value of 0.9 using data from a sample of patients with STD seen at
the Harborview Medical Center. The baseline parameter values for the rate of
sex partner change, stratied by gender, sexual activity, and age, are calculated
from Table 3 using data from the NHSLS and the procedure outlined in Garnett
and Anderson [24, 25]. Briey, this procedure can be described as follows. Let
the relative partner acquisition rate of sexual activity group l relative to the
lowest group be pcl. Similarly, dene the relative partner acquisition rate of age
group i relative to the lowest group as pai. Therefore, the rate of sex partner
change for people in age group 1859 is
ckli =
pclpaic3
3P
l=1
11P
j=3
Nklj(0)
3P
l=1
11P
j=3
Nklj(0)pclpaj
;
where c3 is the weighted mean rate of sex partner change rate. The rates of sex
partner change for the individuals in the age groups 1214, 1517, and over 60
years are calculated in a similar fashion. For individuals in the sexually active
age groups 1859, a value for c3 of 1.3 new partners per year was used in the
analysis [55]. A value for c1of 0.1 and c2 of 0.3 new partners per year was used
for individuals in age groups 1214, and 1517, respectively [1]. It is assumed
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Activity group Proportion of population, % Relative partner Reference
acquisition rate
males, !m females, !f (RPAR), pcl
1 (highest) 2.56 2.56 11.29 [55]
2 11.47 11.47 2.96
3 (lowest) 85.97 85.97 1
Age group RPAR, pai Mean partner acquisition rate, cj
1214 0.11 0.1 [1]
1517 1.18 0.3 [1]
1819
2024
2529
3034
3539
4044
4549
5054
5559
2.42
2.61
2.55
1.72
1.65
1.53
1.38
1.25
1.00
9>>>>>>>>>>>>=>>>>>>>>>>>>;
1.3 [55]
60  69
 70
0:61
0:44

0.5 assumed
males females
Population size, Nk 50,000 50,000
Table 3: Baseline behavioral parameter values for the sexually active population
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that for individuals 60 years and older c4 is 0.5. Other values were used in the
sensitivity analysis.
3.9 Balancing population
To close the model, the total number of people in each gender category k,
(k = f;m), age group i ( i = 1, 2, . . . ,17) and sexual activity group l (l = 1,
2, 3) must be equal to the sum of individuals in each epidemiologic class in the
respective gender, age, and sexual activity groups. That is,
Nmli =
2X
h=1
 
Y hmli + Z
h
mli + U
h
mli +W
h
mli +Q
h
mli + P
h
mli +GW
h
mli

+Xmli + Vmli + Smli + Y
12
mli + Z
12
mli +W
12
mli +Q
12
mli;
For females this requires
Nfli =
2X
b=1
 
2X
h=1
[Y hflib + Z
h
flib + U
h
flib +W
h
flib +Q
h
flib + P
h
flib +GW
h
flib
+
3X
s=1
(CINhslib +DCIN
h
slib + ICIN
h
slib) +
2X
s=1
(CIShslib +DCIS
h
slib
+ICIShslib) +
L;R;DX
s
CChslib] +Xflib + Vflib + Sflib + Y
12
flib
+ Z12flib +W
12
flib +Q
12
flib

+
3X
s=1
TCINsli +
2X
s=1
TCISsli
L;R;DX
s
DCCsli
+
2X
h=1
 
HY hfli +HZ
h
fli +HU
h
fli +HW
h
fli +HQ
h
fli +HP
h
fli +HGW
h
fli

+HXfli +HVfli +HSfli +HY
12
fli +HZ
12
fli +HQ
12
fli +HW
12
fli + SCCli:
As evident from the system of equations described above, the demographic
model, the HPV model, the cancer model, and the genital warts model are fully
integrated, and can only be solved together. The total number of di¤erential
equations in the entire model is 7191.
3.10 Estimates of epidemiologic parameters
A comprehensive search of the literature was conducted in order to obtain base-
line values for the natural history and clinical parameters.
3.10.1 Estimates of natural history parameters
The values of natural history parameters are reported in Tables 45. The way
these estimates were derived is explained elsewhere [46].
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Parameter Estimate Reference
mean duration of acute HPV infection , years [29]
HPV 16/18, 1=(1ki +
P
s 
1
ks) 1.2
HPV 6/11, 1=(2ki + 
2
kg +
P
s 
2
ks) 0.7
progression in the presence of HPV 16/18 per year, %
Normal to CIN1, 1k1 9.4 [38]
Normal to CIN2, 1k2 5.8 [84]
Normal to CIN3, 1k3 5.3 [84]
CIN1 to CIN2, 11i 13.6 [42]
CIN2 to CIN3, 12i 14 [48, 16]
CIN3 to CIS1, 13i 42 [48, 80]
CIS1 to CIS2, 14i 5
CIS2 to LCC, 15i 18
LCC to RCC, 1Li 10 [32, 71, 61]
RCC to DCC, 1Ri 30 [61]
progression in the presence of HPV 6/11 HPV per year, %
Normal to CIN1, 2k1 9.5 [43]
Normal to CIN2, 2k2 1.9 [43, 3, 20, 40, 68]
CIN1 to CIN2, 21i 0 [43, 3, 20, 40, 68]
Normal to genital warts, 2kg 57 [84]
regression in the presence of HPV 16/18 per year, %
CIN1 to normal/HPV, 1f1 32.9 [43, 72]
CIN2 to normal/HPV, 1f2 31 [48, 16, 57]
CIN2 to CIN1, 1f21 13.3 [16]
CIN3 to normal/HPV, 1f3 11 [48]
CIN3 to CIN1, 1f31 3 [48, 16]
CIN3 to CIN2, 1f32 3 [48, 16]
regression in the presence of HPV 6/11 HPV per year, %
CIN1, 2f1 55.2 [43]
genital warts, 2gk 87.5 [84]
hysterectomy rate, i, % [49]
1524 years 0.02
2529 years 0.26
3034 years 0.53
3539 years 0.89
4044 years 1.17
4554 years 0.99
 55 years 0.36
Table 4: Baseline biological parameter values for the HPV and disease compart-
ments and hysterectomy
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Parameter Estimate Reference
age-specic cervical cancer mortality rates, % per year [75]
for LCC, L
1529 years 0.7
3039 years 0.6
4049 years 0.8
5059 years 1.9
6069 years 4.2
 70 years 11.6
for RCC, R
1529 years 13.4
3039 years 8.9
4049 years 11.0
5059 years 10.1
6069 years 17.6
 70 years 28.6
for DCC, D
1529 years 42.9
3039 years 41.0
4049 years 46.7
5059 years 52.7
6069 years 54.6
 70 years 70.3
Table 5: Annual age-specic cervical cancer mortality rates, 19972002
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3.10.2 Estimates of other clinical parameters
The values of screening, diagnosis, and treatment parameters are reported in
Tables 6.
3.10.3 Estimates of vaccine parameters
The e¢ cacy of the vaccine against incident infection (HPV 6/11 or 16/18) was
assumed to be 90%. It was also assumed that infected vaccinated individuals
do not progress to disease [52, 78]. We assumed the vaccine does not a¤ect the
natural course of disease. The duration of immunity conferred by vaccination is
currently unknown. We assumed the duration of protection of HPV vaccination
to be lifelong for the base case as was done in previous models [32] and examined
a duration of 10 years in sensitivity analyses. Given HPV vaccination coverage
is unknown, we assumed that 70% of adolescents will receive a 3-dose vaccine
before they turn 12 similar to the coverage rates used in previous models [71, 32].
Coverage was also assumed to increase linearly from 0% up to 70% during the
rst ve years of the program and remain at 70% thereafter. We assumed that
vaccine coverage for the catch-up program would increase linearly from 0% up
to 50% during the rst 5 years and then drop to 0% after 5 years.
4 Epidemiologic impact of screening and vacci-
nation strategies
To assess the epidemiologic impact of each vaccination strategy several interme-
diate and two nal outcome measures of e¤ectiveness were chosen. Examples
of some of the intermediate outcome are shown in Figures ???? and discussed
below.
4.1 Years of life
The rst nal outcome measure is the total number of years spent alive by the
active population. Thus, the discounted total number of years of life achieved
using strategy a is given by
Y La =
TZ
0
0@ X
k2ff;mg
3X
l=1
17X
i=1
Nkli
1A e tdt
where Nkli is the size of the population of gender k, in sexual activity group l,
and in age group i;  is the discount rate; and T is the planning horizon.
4.2 Quality-adjusted life years
The second nal measure of e¤ectiveness assigns quality of life weights to each
health state and integrates the sum of all these quality-adjusted health states
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Parameter Estimate Reference
Routine cervical screening, coveri, % per year [44]
1014 years 0.6
1519 years 21.0
2024 years 44.8
2529 years 61.6
3034 years 54.9
3539 years 50.5
4044 years 48.1
4549 years 49.1
5054 years 51.1
5559 years 46.7
6064 years 42.5
6569 years 38.9
7074 years 29.6
75-79 years 20.1
80-84 years 11.1
85+ 5.5
Females never screened, %1 5
Liquid-based cytology sensitivity, papsns, %
for CIN1 28 [7]
for  CIN2/3 59 [7]
Liquid-based cytology specicity, papsp, % 94 [7, 14]
Colposcopy sensitivity, colpsn, % 96 [60]
Colposcopy specicity, colpsp, % 48 [60]
Genital wart patients seeking physician care, 1  gs, % 75 [12]
Symptoms recognition, %
LCC, recogL 3.8
RCC, recogR 18
DCC, recogd 90
Cure rate with treatment per year, %
for CIN1, cure1 96 [22]
for CIN2,  2 92 [22]
for CIN3,  3 92 [22]
for LCC, 
L 92 [69]
for RCC, 
R 53 [69]
for DCC, 
D 17
Persistence of HPV after treatment for CIN, % 34 [15]
Table 6: Cervical cytology screening and colposcopy characteristics and rates
of cure and symptom recognition
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over the planning horizon (0; T ). Let qcins, qciss, qccs, qccs, qgwk, and qki
denote the quality of life weights for an individual in the detected health state
CIN stage s, CIS stage s, cervical cancer stage s, genital warts, and normal of
gender k at age i; respectively. The discounted total number of quality-adjusted
life years using strategy a over the planning horizon (0; T ) is given by
QALYa =
TZ
0
e t
(
3X
l=1
17X
i=1
qmi
 
Nmli   (1  qgwm)DGW 2mli

+qfi
"
Nfli   (1  qgwf )(DHGW 2fli +
2X
b=1
DGW 2flib)  (1  qccs)SCCli
 
2X
h=1
 
3X
s=1
(1  qcins)
2X
b=1
DCINhslib +
2X
s=1
(1  qciss)
2X
b=1
DCIShslib
!
 
0@ X
s=L;R;D
(1  qccs)DCCsli
1A359=; dt:
Note that the quality-adjusted years of life for females are reduced by time
spent in diagnosed genital warts, CIN, and cancer statesDCINs, DCCs, DGW ,
and SCC. Malesquality of life deteriorates by spending time with detected
genital warts. The probability of genital warts being recognized and treated is
assumed to be 75%. It is assumed here that if a personss health condition is not
detected, the quality of life of that person will be the same as that of a person
without the condition. This assumption biases the results against the vaccine.
In the sensitivity analysis, the magnitude of the quality of life improvements for
persons with undetected conditions prevented by the vaccine will be quantied.
4.3 Estimates of quality of life weights
Women diagnosed with CIN1 and CIN2/3 were assumed to have quality weight
of 0.91 and 0.87, respectively [62, 54]. The quality weight for genital warts is
assumed to be 0.91 [62]. Females with local and regional cancer are assumed to
have a quality of life weight of 0.76 and 0.67, respectively [62]. A quality weight
for invasive distant cancer of 0.48 was derived from Gold et al [30] using the
25th percentiles of female genital cancer weights. It is assumed that the quality
of life for cervical cancer survivors after successful treatment will continue to be
lower (at 0.76) than that of healthy females [4, 83]. Undiagnosed HPV, genital
warts, CIN, and cervical cancer states and successfully treated CIN states are
assumed to have a quality of life weight similar to those of individuals without
HPV disease. Gender- and age-specic quality weights for other health states
were derived from Gold [30]. Similar values were reported from the Beaver Dam
Health Outcomes study [23]. CIN and cancer health states were multiplied by
the age- and gender-specic weights to reect the variation in quality of life by
age and gender groups.
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Condition Estimate Reference
females males
genital warts, qgwk 0.91 0.91 [62]
CIN1, qcin1 0.91 [62]
CIN2, qcin2 0.87 [62]
CIN3, qcin3 0.87 [62]
CIS, qciss 0.87 [62]
EICC, qccL 0.76 [62]
RLICC, qccR 0.67 [62]
DLICC, qccD 0.48 [30]
Cancer survivors, qccs 0.76 [83]
No condition, qki
1217 years 0.93 0.93 [30]
1834 years 0.91 0.92 [30]
3544 years 0.89 0.90 [30]
4554 years 0.86 0.87 [30]
5564 years 0.80 0.81 [30]
6574 years 0.78 0.76 [30]
 75 years 0.70 0.69 [30]
Table 7: Quality of life weights
5 Economic consequences of screening and vac-
cination strategies
The total costs of each strategy includes costs of cytology screening per unit
time, cost of vaccination, lifetime cost of treating detected genital warts, CIN
and invasive cancer cases, and the cost of following false positive results of
screening.
5.1 Screening costs
The cost of cytology screening per unit time is the product of the cost per test
scn, the test compliance rate coverib given the frequency of administering the
test per unit time (e.g., every year), and the size of the population eligible for
screening
P
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slib]. For simplicity, it is assumed that females in the hysterectomy class
are not screened. However, this may not be the case as suggested by recent
studies [70]. The cost of following false positive results of the cytology test is the
product of the cost of colposcopy colp of those females who do not have a repeat
cytology test, one minus cytology specicity papsp and the size of the screened
population that is truly negative
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colposcopy is not 100% specic, to this it should be added the cost of a false
positive colposcopy result. This, in turn, equals the product of the cost of
biopsy biopsy, one minus colposcopy specicity colsp and the size of the screened
population that has false cytology results. We also assumed that females in
categories TCINs; ICINs; ICINs; and SCC receive annual Pap tests, some of
which will be false positives resulting in additional colposcopies and biopsies.
Total screening costs associated with strategy a at time t are
Screena(t) =
scn f
X
l
X
i
(
X
b
coverib  (Xflib + Vflib + Sflib + Y 12flib + Z12flib +W 12flib
+Q12flib +
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h
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h
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5.2 Treatment costs
Treatment costs of genital warts, CIN, and cancer cases are the product of
the number of cases detected and treated and the cost of treatment. Cases of
genital warts occur at rate (1 gs)
P
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12
klib)g at a cost of cgwk per case. Because it is assumed that the rate of
treatment for diagnosed CIN is  s and all cancer cases are treated, the number
of cases treated at time t is the total number of treated CIN and cancer detectedP
h
P
l
P
i
P
b[
P
s  sDCIN
h
slib+
P
s  3+sDCIS
h
slib+
P
s sibCC
h
slib)]. The cost
of treating CIN and cancer at stage s is denoted by ctcins and ctccs, respectively.
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Thus, total treatment costs at time t if strategy a is adopted is:
Treata(t) =X
l
X
i
X
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5.3 Vaccination costs
Total vaccination costs at time t include the cost of the vaccine and the number
of people vaccinated
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vaccination costs at time t associated with strategy a are:
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5.4 Total costs
Discounted total cost over the planning horizon (0; T ) of following strategy a is
Costa =
TZ
0
[Screena(t) + Treata(t) + V accinatea(t)] e
 tdt:
5.5 Estimates of costs
Direct medical costs for screening and diagnosis were estimated from the 2001
Medstat Marketscan R commercial insurance database [56] and updated to 2005
dollar values by using the medical care component of the U.S. consumer price
index [77]. The direct medical costs in 2005 of liquid-based cytology were es-
timated at $99. The cost of colposcopy was $165 and colposcopy with cervical
biopsy at the same visit was $318. The direct medical costs of treatment of CIN
and cervical cancer were based on the results of Kim et al [50] and updated to
2005 dollar values [77]. The costs of CIN 1 were $1554, CIN 2/3 $3483, local
invasive cervical cancer $26,470, regional invasive cervical cancer $28,330, and
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Condition Estimate Reference
females males
cytology test, scn $99 [56]
colposcopy, colp $165 [56]
colposcopy and biopsy, biopsy $318 [56]
genital warts, cgwk $489 $489 [41]
CIN1, ctcin1 $1554 [50]
CIN2, ctcin2 $3483 [50]
CIN3/CIS, ctcin3 $3483 [50]
EICC, ctccL $26,470 [50]
RLICC, ctccR $28,330 [50]
DLICC, ctccD $45,376 [50]
Table 8: Cost of screening, diagnosis, and treatment
local invasive cervical cancer $45,376. Treatment of genital warts is assumed to
cost $489 in 2005 dollars [41].
5.6 Cost-e¤ectiveness ratio
To compare mutually exclusive vaccination strategies a and a0, we calculate the
incremental cost-e¤ectiveness ratio [82]
Costa   Costa0
QALYa  QALYa0 :
6 Analysis using the model
6.1 Simulations with the baseline estimates of the para-
meters
Mathematica R (Wolfram Research, Champaign, IL) version 5.2 was used to
generate numerical solutions of the model. The NDSolve subroutine in Math-
ematica is a general numerical di¤erential equations solver. Since the model
consists of non-sti¤ ODEs, the Explicit Runge Kutta methods, with adaptive
embedded pairs of 2(1) through 9(8), provide accurate and less expensive solu-
tions [85]. Other methods such as the Predictor-Corrector Adams method, with
orders 1 through 12, produced the same results, but took longer to compute the
solution.
The following strategy for simulations was followed. First, the baseline para-
meter estimates were used to solve the model for the pre-vaccination steady-state
values of the variables. Second, the pre-vaccination data were used as initial val-
ues for the vaccination model and the model was solved for the entire time path
of the variables until the system approached the steady state (approximately
100 years). The solution approximates the potential impact of various HPV
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vaccination programs, including routine vaccination of 12-years old individuals.
Finally, once the solution is obtained the results can be presented for various
outcomes in many di¤erent formats.
6.2 Model validation
The validity of a complex model like this cannot be established directly. In-
stead, its face validity may be judged by how reasonable model assumptions are
[34, 81]. In the process of building this model, we comprehensively reviewed
previous relevant models and consulted experts on the natural history of HPV
infection and HPV-related diseases. A comprehensive review of the literature
was conducted to identify studies to inform model inputs. To facilitate inde-
pendent review of the model and the ability to replicate its results, all model
equations and inputs are made available. All model equations and inputs are
programmed in MathematicaTM (Wolfram Research, Champaign, IL). A series
of tests were performed to debug and establish the technical accuracy of the
Mathematica programs. For example, the sum of the number of individuals of
a given gender, age, and sexual activity group in each compartment is veried
to be equal to the total number of people Nkli at each point in time (see section
3.9 on balancing population). Finally, the predictive validity of the model was
evaluated by looking at age-specic HPV prevalence, CIN, genital warts, and
cervical cancer incidence rates predicted by the model and comparing them with
those reported in the literature [29, 47, 73, 74, 75, 41, 45]. The model predictions
were well within the range of values found in the literature. For example, the
predicted HPV 16/18 attributable cervical cancer incidence curve in the absence
of screening had a shape and magnitude at peak (55.9 per 100,000 women years
for age 5054) similar to that estimated for unscreened populations [33, 58].
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